Indian Journal of Cancer Home 

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2016  |  Volume : 53  |  Issue : 3  |  Page : 460--463

Eribulin in heavily pretreated metastatic breast cancer: A tertiary care center experience from India

J Bajpai, A Ramaswamy, S Gupta, J Ghosh, S Gulia 
 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Correspondence Address:
J Bajpai
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
India

INTRODUCTION: Heavily pretreated metastatic breast cancer (MBC) remains a major therapeutic challenge with limited treatment options this. Eribulin, an anti-microtubule agent, has been recently approved for this indication. There are sparse data from the Asian region for eribulin and merits exploration. MATERIALS AND METHODS: This was a single institution retrospective analysis of MBC patients treated with eribulin from 2013 to 2014. These patients had received at least 2 lines of prior therapy for metastatic disease. Patients received standard doses of eribulin and were monitored for toxicity and responses. RESULTS: Eighteen patients were included in this analysis. They had received a median of 6 lines of therapy previously (including adjuvant treatment) and had significant visceral involvement (median 3 organs). A median of 4 cycles of eribulin was delivered. There were no complete responses; partial responses were seen in 33% (6/18), stable disease status in 28% (5/18) patients, and progressive disease on eribulin in 39% (7/18) patients. The median progression-free survival was 15 weeks (3.5 months), and median overall survival was 27 weeks (6.2 months). Significant Grade 3/4 toxicities seen included peripheral neuropathy in 28% (5/18) and neutropenia in 28% (5/18) of patients while dose reductions were required in 22% (4/18) of patients. CONCLUSION: Eribulin offers a viable, well-tolerated regimen that provides meaningful clinical benefit in Indian patients with MBC.


How to cite this article:
Bajpai J, Ramaswamy A, Gupta S, Ghosh J, Gulia S. Eribulin in heavily pretreated metastatic breast cancer: A tertiary care center experience from India.Indian J Cancer 2016;53:460-463


How to cite this URL:
Bajpai J, Ramaswamy A, Gupta S, Ghosh J, Gulia S. Eribulin in heavily pretreated metastatic breast cancer: A tertiary care center experience from India. Indian J Cancer [serial online] 2016 [cited 2020 Jul 7 ];53:460-463
Available from: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2016;volume=53;issue=3;spage=460;epage=463;aulast=Bajpai;type=0